Cancer reportsPub Date : 2025-10-01DOI: 10.1002/cnr2.70356
M. Garcia Fasanella, A. Mozos, J. Briones, J. F. Nomdedeu, S. Novelli
{"title":"Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis","authors":"M. Garcia Fasanella, A. Mozos, J. Briones, J. F. Nomdedeu, S. Novelli","doi":"10.1002/cnr2.70356","DOIUrl":"https://doi.org/10.1002/cnr2.70356","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hairy cell leukemia (HCL) is a rare disorder characterized by splenomegaly, pancytopenia, and proliferation with “hairy” lymphocytes. Treatment is based on purine analogs and anti-CD20 antibodies, often resulting in significant adverse effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The objective of this study is to describe the frequency, clinical, and biological characteristics of a historic cohort of HCL patients in our center and the most common side effects related to treatment with purine analogs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>This study analyzed 21 patients treated between 2009 and 2023, focusing on clinical characteristics, treatment response, complications, and survival outcomes. Cladribine treatment achieved complete response in 77.8% of patients. The 5-year OS and PFS were 100% and 91.7%, respectively. Infections, pathogens such as herpes viruses and mycobacteria, were major complications, impacting 38% of patients. Severe skin reactions were noted in patients treated with cladribine.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study highlights cladribine's effectiveness in inducing remission in HCL patients, pointing out the significant risks of infections and other adverse effects. Introducing targeted treatments like BRAF inhibitors provides promising alternatives, especially for resistant patients or those intolerant to purine analogs. Future strategies should focus on integrating targeted therapies to reduce treatment-related morbidity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70356","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Notch1 Mutation Represents a Potential Therapeutic Target to Enhance Immune Recognition in Oral Squamous Cell Carcinoma","authors":"Takahiro Iwamoto, Kazuhiro Ogi, Takafumi Nakagaki, Takashi Sasaya, Sho Miyamoto, Koyo Nishiyama, Kenta Sasaki, Shintaro Sugita, Yasushi Sasaki, Akihiro Miyazaki","doi":"10.1002/cnr2.70345","DOIUrl":"https://doi.org/10.1002/cnr2.70345","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Notch1</i>, a tumor suppressor gene, is one of the most frequently mutated genes in head and neck squamous cell carcinoma (HNSCC). Therefore, it is clinically important to investigate the effects of <i>Notch1</i> mutations on antitumor immunity in oral squamous cell carcinoma (OSCC), a subset of HNSCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study investigated <i>Notch1</i> mutations and the expression of immune-related proteins. We also examined the influence of <i>Notch1</i> mutations on the immune microenvironment using a public database.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>We examined the expression of <i>Notch1–4</i> in OSCC cell lines using qPCR. After <i>Notch1</i> knockdown, OSCC cell proliferation and migration were analyzed using CCK8 and wound healing assays, respectively. Localization of programmed cell death ligand 1 (PD-L1) was assessed by western blot and flow cytometry, while PD-L1 expression was evaluated by western blot. In the somatic mutation analysis of 47 OSCC patients, the relationship between tumor-infiltrating CD8<sup>+</sup> T cells and PD-L1 expression was analyzed using immunohistochemical (IHC) staining. Furthermore, data from The Cancer Genome Atlas (TCGA) were analyzed using multiple online bioinformatics tools to compare the characteristics of <i>Notch1</i> mutations in HNSCC. The expression of <i>Notch1</i> varied depending on the OSCC cell line phenotype, and Notch1 mutation was significantly correlated with tumor growth but not with tumor infiltration. In <i>Notch1</i> knockdown, PD-L1 expression on the tumor cell surface increased, while cytoplasmic PD-L1 expression decreased. Among the 47 OSCC patients analyzed, seven (14%) had <i>Notch1</i> mutations. Of those, five patients (71%) exhibited high tumor-infiltrating CD8<sup>+</sup> T cells and <i>Notch1</i> mutation. Online bioinformatics analysis using the xCell algorithm revealed that Notch1-mutated tumors had significantly higher levels of naïve CD8<sup>+</sup> T cells compared to Notch1 wild-type tumors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings highlight <i>Notch1</i> mutation as a potential therapeutic target for immune recognition in OSCC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70345","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145197205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer reportsPub Date : 2025-09-23DOI: 10.1002/cnr2.70290
Traci L. Parry, Nicole Wood, Jacob Garritson, Michael J. Muehlbauer, Louisa Tichy, Jason T. Brantley, James R. Bain, Reid Hayward
{"title":"Early Markers of Cardiac and Skeletal Muscle Metabolic Derangement in the Apc(min/+) Male Mouse","authors":"Traci L. Parry, Nicole Wood, Jacob Garritson, Michael J. Muehlbauer, Louisa Tichy, Jason T. Brantley, James R. Bain, Reid Hayward","doi":"10.1002/cnr2.70290","DOIUrl":"10.1002/cnr2.70290","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Cancer cachexia is a metabolic and wasting disease that occurs in up to 80% of cancer patients. Currently, there are no clear diagnostic criteria, its effects are irreversible, and it cannot be treated. Most patients progress undetected to late stages of cancer cachexia, stop responding to traditional treatment, and die without an effective intervention. While the literature has begun to characterize late (refractory) cachexia muscle metabolic changes, less is known about early changes that may precede obvious muscle dysfunction and wasting. Therefore, this investigation aimed to characterize early phase heart and skeletal muscle metabolic changes in a preclinical model of colorectal cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Apc(min/+) mouse spontaneously forms tumors along the intestinal tract and is a well-accepted preclinical colorectal cancer model. To identify early changes in muscle metabolism during colorectal cancer development, heart and gastrocnemius tissues from 15-week-old male Apc(min/+) and litter-matched non-carrier mice (wildtype) were analyzed by untargeted GC/MS metabolomics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the heart, metabolic pathways related to taurine/hypotaurine metabolism; biosynthesis of unsaturated fatty acids; alanine, glutamate, and aspartate; arginine and proline; and arginine biosynthesis were affected by colorectal cancer. In skeletal muscle, metabolic pathways involving arginine biosynthesis; alanine, glutamate, aspartate, and proline metabolism were affected by cancer cachexia. Taken together, these data demonstrate altered arginine metabolism and proline metabolism in hearts and skeletal muscle of cachectic mice. Interestingly, cardiac muscle showed a non-preferential fuel switch towards less energetically favorable glycolysis (vs. fatty acid metabolism) that coincided with cardiac dysfunction, while skeletal muscle exhibited glucose dysregulation and possible insulin resistance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These data characterize early cardiac and skeletal muscle metabolic derangements that lead to muscle dysfunction and atrophy during colorectal cancer. Such data could help identify patients in early phases of cachexia or identification of cardiac and skeletal muscle specific therapeutic targets aimed at early intervention.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12455247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Psychometric Properties of the Post-Traumatic Stress Disorder Questionnaire (PCL-5) for Cancer Patients in Iran","authors":"Maryam Hasannezhad Reskati, Hamid Sharif-Nia, Seyed Hamzeh Hosseini, Hossein Azadeh, Behnoush Yazdirad, Reza Alizadeh-Navaei, Forouzan Elyasi","doi":"10.1002/cnr2.70331","DOIUrl":"10.1002/cnr2.70331","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cancer is known as a common chronic disease that many aspects of its diagnosis and treatment may manifest traumatic episodes and lead to the post-traumatic stress disorder (PTSD) associated with cancer. Avoidance symptoms in PTSD often delay individuals from seeking professional assistance. Therefore, the PTSD Checklist for the Diagnostic and Statistical Manual of Mental Disorders-5th Edition or DSM-5 (PCL-5) can evaluate PTSD conceptually and psychometrically instead of avoidance responses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Accordingly, this research aimed to explore the psychometric features of the PCL-5 Persian version in the population of gastrointestinal cancer patients in Iran.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>As the instrument of the research, the Persian version of PCL-5 was conducted on 486 gastrointestinal cancer patients who referred to Baghban Clinic, the cancer research center of “REDACTED” University of Medical Sciences, and Imam Khomeini Hospital in Sari from July 2021 to May 2022. The used questionnaire survey included two sections. The first part consisted of questions regarding participants' profiles, such as age, gender, and job status. In the second section, the Posttraumatic Stress Disorder item 20 was used to measure (PCL-5) Participants were asked to respond to each statement with a 5-point range Likert scale from 0 to 4.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Exploratory factor analysis showed four-factor structures for PCL-5, explaining 43.17% of the total variance. According to the mentioned analysis, each fit index verified the model fit. All internal consistency coefficients were also predicted to be acceptable reliability. It can be concluded from the data that highlighted good psychometric features for PCL-5, suggesting the effectiveness of this scale for the screening of PTSD in gastrointestinal cancer patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study indicates the effectiveness and usefulness of the Persian version of the PCL-5 scale for assessing post-traumatic stress in the cases suffering from gastrointestinal cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70331","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Plasma Circular RNAs in Breast Cancer: From Biomarker Potential to Functional Significance","authors":"Sepideh Abdollahi, Ghasem Azizi-Tabesh, Amirhossein Sangi Nasab Lahijan, Arman Rajabi Matak, Pantea Izadi","doi":"10.1002/cnr2.70316","DOIUrl":"10.1002/cnr2.70316","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer remains life-threatening, but mortality declines with earlier diagnosis. Conventional work-ups rely on invasive tissue biopsy of imaging-detected masses. Liquid biopsy offers a minimally invasive alternative by assessing circulating biomarkers. Among these, circular RNAs (circRNAs) are compelling because their covalently closed structure confers high stability in blood. Recent studies connected circRNAs to malignancy process in breast and proposed their diagnostic potential. This review has collected relevant evidence on circRNA biogenesis, functions and their dysregulated plasma signatures in breast cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>Multiple plasma circRNAs showed diagnostic and prognostic signal in breast cancer. Upregulated hsa_circ_0001785 outperformed traditional plasma tumor markers (CEA and CA15-3) for detection of breast cancer; higher plasma levels associated with distant metastasis, advanced TNM stage, and higher grade. Elevated hsa circ_0108942 in plasma correlated with larger tumors, lymph node involvement, and advanced stage. Hsa circ 0042881 was increased in tumors and plasma and correlated with higher TNM stage and larger tumor size. Conversely, downregulated plasma circRNAs, included hsa circ 0068033 with inverse links to stage and tumor size, and hsa_circ_0104824, both are promising for non-invasive diagnosis of breast cancer and prognostication of breast cancer. Subtype-specific circRNAs are also noted: circEGFR was upregulated in triple-negative subtype and aligned with aggressive clinical features and reduced chemotherapy sensitivity, whereas circ-FOXO3 was downregulated and associated with lymph-node metastasis, consistent with a tumor-suppressive role.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Plasma circRNAs represent a biologically grounded class of minimally invasive biomarkers with promise for early detection, risk stratification, and real-time monitoring in breast cancer. To progress toward clinical utility, priorities are larger multi-center cohorts, harmonized reporting standards, head-to-head comparisons with established markers, transparent cut-offs and prospective evaluation of multi-marker panels integrated with imaging and clinicopathologic variables.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12445201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Disease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B-Cell Lymphoma-Type Richter Syndrome: A Case Report in an Elderly Patient","authors":"Takumi Nishikawa, Masuho Saburi, Shogo Urabe, Eiichi Ohtsuka","doi":"10.1002/cnr2.70349","DOIUrl":"10.1002/cnr2.70349","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Richter syndrome (RS) is an aggressive transformation of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with poor prognosis. No standard treatment for RS has been established. Epcoritamab, a CD3xCD20 bispecific antibody, may offer clinical benefit.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>An 80-year-old woman was diagnosed with SLL in 2017 and remained untreated for nearly 6 years. In 2023, she developed a bulky abdominal tumor. Although the initial biopsy showed SLL progression without transformation, subsequent treatments with acalabrutinib, venetoclax plus rituximab, and bendamustine plus rituximab failed. In 2024, transformation to diffuse large B-cell lymphoma-type RS (DLBCL-RS) was confirmed. Two lines of cytotoxic regimens were ineffective, with rapid tumor growth. Epcoritamab was initiated as third-line therapy. Grade 1–3 cytokine release syndrome occurred but resolved with standard management. No neurotoxicity was observed. Partial response (PR) was achieved by week 12, and the patient has maintained PR for 10 months. Infections including COVID-19 and cytomegalovirus were managed successfully, and immunoglobulin replacement was introduced for hypogammaglobulinemia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case highlights the potential of epcoritamab as an important treatment option for elderly patients with refractory DLBCL-RS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer reportsPub Date : 2025-09-16DOI: 10.1002/cnr2.70286
Yao Wang, Jianning Xu, Jun Qian, Jian Qiu, Min Zhu, Daquan Wang
{"title":"Retrospective Analysis of Risk Factors and Prediction Model of Cervical Anastomotic and Intrathoracic Anastomotic Leakage After Radical Esophagectomy","authors":"Yao Wang, Jianning Xu, Jun Qian, Jian Qiu, Min Zhu, Daquan Wang","doi":"10.1002/cnr2.70286","DOIUrl":"10.1002/cnr2.70286","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Esophagogastric anastomotic leakage is a common complication after esophageal cancer surgery. Therefore, how to treat and predict is the focus of clinicians' research.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To analyze the risk factors of cervical and intrathoracic anastomotic leakage after radical resection of esophageal cancer and establish a prediction model to provide a basis for early clinical prevention and treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed the clinical data of 776 esophageal squamous cell carcinoma patients who underwent Sweet (<i>n</i>=115), Ivor-Lewis (<i>n</i>=278), and McKeown (left neck anastomosis) (<i>n</i>=383) esophagectomy at Yancheng First People's Hospital from August 2019 to December 2021. Univariate and logistic regression models were used to analyze the independent risk factors of anastomotic leakage after esophageal cancer surgery, and a nomogram prediction model was established.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 776 patients, 95 experienced postoperative anastomotic leakage, with an incidence of 12.2%. There were 63 cases of cervical anastomotic leakage and 32 cases of intrathoracic anastomotic leakage. The multivariate logistic regression analysis showed that BMI, high blood pressure, chronic bronchitis, peptic ulcer, operation way, anastomotic location, and postoperative albumin were independent risk factors for postoperative anastomotic leakage of esophageal cancer (<i>p</i> < 0.05). Our nomogram prediction model yielded a high predictive value, with an area under the receiver operating characteristic curve of 0.765 (95% CI 0.716–0.814).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The occurrence of anastomotic leakage after esophageal cancer surgery is related to various factors, including BMI, hypertension, chronic bronchitis, peptic ulcer, operation way, anastomotic way, postoperative albumin, and anastomotic location. The clinical prediction model can promote the early detection, diagnosis, intervention, and treatment of anastomotic leakage and shorten the hospitalization time of patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer reportsPub Date : 2025-09-15DOI: 10.1002/cnr2.70352
Dikshita Deka, Alakesh Das, Nabajyoti Baildya, Shruthi Nagainallur Ravichandran, Surajit Pathak, Antara Banerjee, Asim K. Duttaroy
{"title":"4-Phenylbutyric Acid Reduces the Proliferation in Colon Cancer Cell Lines Through Modulating the Cell Cycle Regulatory Genes: An In Silico and In Vitro Approach","authors":"Dikshita Deka, Alakesh Das, Nabajyoti Baildya, Shruthi Nagainallur Ravichandran, Surajit Pathak, Antara Banerjee, Asim K. Duttaroy","doi":"10.1002/cnr2.70352","DOIUrl":"10.1002/cnr2.70352","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Endoplasmic reticulum stress (ER-stress) is recognized to have a major role in both the onset and progression of various diseases, including cancer. Therefore, much research has focused on developing chemical chaperones or small compounds to reduce ER-stress in various disease conditions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The present study investigates the effects of 4-phenylbutyric acid (4-PBA) on the modulation of proliferation and inflammatory responses in colon cancer cell lines by possibly regulating ER-stress-related protein expression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials</h3>\u0000 \u0000 <p>Molecular docking and molecular dynamics simulations were performed to determine the binding affinity of 4-PBA with ER-stress-regulating proteins (IRE1-α, PDI, GRP78, PERK, NRF2). To validate our hypothesis, the expression levels for ER-stress-regulating genes (<i>GRP78, XBP1, ATF6, PDI, PERK</i>), pro-inflammatory genes (<i>CXCL12, MCP1, COX2, CCR5</i>), and the cell-cycle regulatory genes (<i>CDK6, CCND1</i>), as well as the inflammatory proteins (IL-6, IFN-γ, and CXCL10) expression and level of catalase and ROS, were studied in colon cancer cell lines before and after treatment of different concentrations of 4-PBA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p><i>In silico</i> analysis showed that 4-PBA could bind with IRE1-α and PERK ER-stress proteins strongly, with the binding energy of −6.8 and −6.5 Kcal/mol. Treatment with 4-PBA showed downregulation of pro-inflammatory genes, along with the ER-stress and cell-cycle regulatory genes. The reduced expression of pro-inflammatory proteins along with ROS and subsequent elevation in catalase levels by 4-PBA in colon cancer cell lines indicates a correlation between ER-stress and inflammatory response.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study revealed that 4-PBA has anti-inflammatory and anticarcinogenic properties, providing new avenues for future research.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12435982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Identification of Tumor Antigens and Immune Subtypes in Hepatocellular Carcinoma From a Multiomics Perspective","authors":"Chunming Wang, Lei Cai, Qingyu Xie, Cheng Zhang, Xuefang Chen, Peng Cui, Guoqiang Wang, Shangli Cai, Yusheng Han, Kaihang Zhong, Guolin He, Shunjun Fu, Yuyan Xu, Junming He, Mingxin Pan","doi":"10.1002/cnr2.70300","DOIUrl":"https://doi.org/10.1002/cnr2.70300","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Immunotherapies including immune checkpoint inhibitors and tumor antigen based vaccines have revolutionized cancer treatment. However, immune signatures of hepatocellular carcinoma (HCC) have not been thoroughly studied from a multiomics perspective.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>In this study, we aimed to identify the potential tumor antigens and immune subtyping for HCC using multiomics data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>The study included 159 HCC patients with genome, transcriptome, proteome, and phosphoproteome data. Two potential tumor antigens, ZNF831 and SYNE1, showed significant superior prognostic effects and positive correlations with antigen presenting cells, which provided promising candidates for the development of tumor antigen-based mRNA vaccine. A multiomics clustering using the most variable tumor antigen genes of transcriptome, proteome, and phosphoproteome was performed, resulting in two HCC subtypes with distinct clinical and molecular features. In order to further explore the complex tumor microenvironment, we implemented an immune subtyping using 30 most important immune-related features generated from the random forest algorithm. Four immune subtypes were constructed, which exhibited diverse molecular attributes including immune cell activities, angiogenesis, cell proliferation, and the expression of tumor antigen genes, immune checkpoints, and immunogenic cell death modulators.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In summary, we found two potential tumor antigens, ZNF831 and SYNE1, and identified four immune subtypes of HCC with distinct molecular features. Our study provides novel insights into the development of cancer vaccine and precision medicine of immune oncology in HCC, which may benefit clinical practice in the future.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70300","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145057755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer reportsPub Date : 2025-09-15DOI: 10.1002/cnr2.70321
Elham Tahami, Abolfazl Akbari, Reza Nekouian
{"title":"Assessment of Expression LncRNA-xloc-000303, lncRNA-LOC152578 and hsa-miR-29a in Patients Diagnosed With Colon Cancer in the Pre-Treatment Stage","authors":"Elham Tahami, Abolfazl Akbari, Reza Nekouian","doi":"10.1002/cnr2.70321","DOIUrl":"10.1002/cnr2.70321","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Employing a panel of biomarkers may enable the early diagnosis of colorectal cancer. Among these biomarkers, long non-coding RNAs (LncRNAs) and microRNAs (miRNAs) are significant due to their crucial roles in biological and metabolic processes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Therefore, the objective of this research was to evaluate the diagnostic value of the biomarkers LncRNA-xloc-000303, lncRNA-LOC152578, and miR-29a in the pre-treatment stage of colorectal cancer in Iranian patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>In this study, 30 tumor tissue samples and 30 adjacent healthy tissue samples were collected, and RNA was extracted using the Trizol kit. Subsequently, the relative expression of the candidate microRNA and LncRNAs was analyzed using real-time PCR. The obtained gene expression data were then analyzed using REST software.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In this study, it was found that the expression of LncRNA-xloc-000303 in tumor tissues significantly increased compared to healthy tissue (<i>p</i> < 0.001). Additionally, the analysis revealed that the expression level of lncRNA-LOC152578 showed an increase in tumor tissues compared to healthy tissues (<i>p</i> = 0.57), although these changes were not statistically significant. The results of the hsa-miR-29a expression analysis indicated a down regulation in tumor tissues compared to healthy tissues; however, this change was also not statistically significant (<i>p</i> = 0.34).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The results indicated that the expression changes of LncRNA-xloc-000303 in cancer tissue were significant compared to adjacent healthy tissue, suggesting its potential use as a biomarker for diagnosing colorectal cancer. However, further studies are needed to evaluate the biomarker specificity of lncRNA-LOC152578 and hsa-miR-29a. This study was conducted in an Iranian population and its results can be used in the future for personalized medicine in the prevention and treatment of colorectal cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12435981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}